Abstract
In This Issue...
Patient recruitment and retention in clinical trials is wide recognized as the
leading bottleneck in the new drug development pipeline, and it is likely to
remain an area of heightened concern for the next five years. As the
recruiting culture becomes more sophisticated with the involvement of multiple
service vendors and the forces affecting patient enrollment grow more numerous
and complex, pharmaceutical companies are striving to discover new strategies
to facilitate enrollment in clinical trials. This report explores how new
approaches to recruitment that are multifaceted, trial-specific, data-driven,
and customer-focused can be used to ease patient enrollment delays, which
significantly impact R&D budgets and can even directly result in millions of
dollars of lost sales.
| 
View Cart
